Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.

Conventional chemotherapy has failed to substantially prolong survival for patients with advanced follicular lymphoma. To improve outcomes, the German Low-Grade Lymphoma Study Group (GLSG) initiated a randomized trial to compare the effect of potentially curative myeloablative radiochemotherapy followed by autologous stem cell transplantation (ASCT) with interferon-alpha (IFN-alpha) maintenance therapy in first remission. Three hundred seven patients (younger than 60 years) with follicular lymphoma were recruited into the trial from 130 institutions. After 2 cycles of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) or mitoxantrone-chlorambucil-prednisone (MCP) induction chemotherapy, patients were randomly assigned to either the ASCT or the IFN-alpha group. The respective therapy was started when patients achieved complete or partial remission after induction chemotherapy. Two hundred forty patients with follicular lymphoma are evaluable for the comparison of ASCT and IFN-alpha. In patients who underwent ASCT, the 5-year progression-free survival (PFS) rate was 64.7%, and in the IFN-alpha arm it was 33.3% (P < .0001). As expected, acute toxicity was higher in the ASCT group, but early mortality was below 2.5% in both study arms. In this randomized, multicenter trial, high-dose radiochemotherapy followed by ASCT significantly improved PFS compared with IFN-alpha in patients with follicular lymphoma when applied as consolidation in first remission. Longer follow-up is necessary to determine the effect of ASCT on overall survival.

[1]  J. Shamash,et al.  Prognostic factors in mesothelioma. , 2002, Lung cancer.

[2]  Ruta Bajorunaite,et al.  Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. , 2003, Blood.

[3]  M. Sydes,et al.  High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  W. Hiddemann.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  T. Barbui,et al.  Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). , 2003, Blood.

[6]  Roey J. Amir,et al.  Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia. , 2003, Blood.

[7]  C. Huber,et al.  Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma , 2003, Bone Marrow Transplantation.

[8]  M. Fricová,et al.  Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas. , 2003, Neoplasma.

[9]  D. Maloney.  Rituximab for follicular lymphoma. , 2003, Current hematology reports.

[10]  T. Chisesi,et al.  High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). , 2002, Blood.

[11]  R. Brezinschek,et al.  Rituximab (anti‐CD20 monoclonal antibody) as consolidation of first‐line CHOP chemotherapy in patients with follicular lymphoma: a phase II study , 2002, European journal of haematology.

[12]  C. Gisselbrecht,et al.  High-dose therapy for indolent lymphoma. , 2002, Critical reviews in oncology/hematology.

[13]  R. Pettengell,et al.  Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma , 2002, Bone Marrow Transplantation.

[14]  M. Czuczman,et al.  Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. , 2002, Seminars in oncology.

[15]  G. Hess,et al.  Rituximab as in vivo purging agent in autologous stem cell transplantation for relapsed B-NHL. , 2002, Annals of hematology.

[16]  N. Schmitz,et al.  Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant? , 2001, Annals of Hematology.

[17]  S. Horning,et al.  High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. , 2001, Blood.

[18]  Y. Kuroda,et al.  [Phase I study of super high-dose chemotherapy for liver cancer with percutaneous isolated hepatic perfusion (PIHP) and peripheral blood stem cell transplantation (PBSCT)]. , 2000, Gan to kagaku ryoho. Cancer & chemotherapy.

[19]  B. Glimelius,et al.  Long‐term follow‐up of autologous stem‐cell transplantation for follicular and transformed follicular lymphoma , 2000, European journal of haematology.

[20]  S. Hohaus,et al.  Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT) , 2000, Bone Marrow Transplantation.

[21]  M. Ghielmini,et al.  The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  A. Pileri,et al.  Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. , 2000, Blood.

[23]  J. Gribben,et al.  Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. , 1999, Blood.

[24]  T. Lister,et al.  Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  W. Hiddemann,et al.  Interferon alfa for the treatment of follicular lymphomas. , 1998, The cancer journal from Scientific American.

[27]  L. Schwartzberg,et al.  High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin’s lymphoma , 1998, Bone Marrow Transplantation.

[28]  J. Gribben,et al.  High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. , 1996, Blood.

[29]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[30]  S. Horning.  Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.

[31]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[32]  J. Gribben,et al.  Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. , 1991, The New England journal of medicine.

[33]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .